Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

The list includes the U.S., the U.K., the European Union, Saudi Arabia, and Bahrain. Casgevy, developed with Vertex Pharmaceuticals, treats sickle cell disease (SCD) and transfusion-dependent ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work on every CF case. But Vertex's newest blockbuster, Trikafta -- approved in ...

Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. It will seek label expansions thereafter, including ...